| Authors: |
Tomikawa E; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Toray Industries, Inc., 6-10-1 Tebiro, Kamakura-shi, Kanagawa 248-8555, Japan., Sakai S; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, Shizuoka 410-2321, Japan., Yamagiwa Y; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Senju Pharmaceutical Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan., Kangawa Y; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Nippon Boehringer Ingelheim Co., Ltd., 6-7-5 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan., Kagawa Y; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Novartis Pharma K.K., 1-23-1 Toranomon, Minato-ku, Tokyo 105-6333, Japan., Kato Y; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Shionogi & Co., Ltd., 3-3-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan., Kojima K; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Kyowa Kirin Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan., Inomata A; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; FUJIFILM Toyama Chemical Co., Ltd., 4-1 Shimookui 2-chome, Toyama 930-8508, Japan., Matsumoto I; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan., Sato G; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan., Suzuki M; AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Kyowa Kirin Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731, Japan. |
